富马酸丙酚替诺福韦与富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎的临床疗效及安全性

Clinical efficacy and safety of tenofovir alafenamide fumarate and tenofovir disoproxil fumarate in the treatment of chronic hepatitis B

目的:比较富马酸丙酚替诺福韦(TAF)与富马酸替诺福韦二吡呋酯(TDF)治疗慢性乙型肝炎的临床疗效及安全性。方法:选择2018年5月至2020年5月在我院治疗的84例慢性乙型肝炎患者,按照随机数字表法将其分为2组,各42例。对照组口服TDF治疗,观察组口服TAF治疗,均连续治疗6个月。比较2组临床疗效、肝功能及不良反应。结果:2组患者治疗总有效率及治疗前后丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)水平比较,差异均无统计学意义(P>0.05);2组患者治疗后ALT及AST水平均低于本组治疗前(P<0.05);观察组不良反应总发生率低于对照组(P<0.05)。结论:慢性乙型肝炎患者采用TAF或TDF治疗均可达到治疗的目的,促进患者病情恢复,改善肝功能,但TAF治疗安全性更高。

Objective:To observe the clinical efficacy and safety of tenofovir alafenamide fumarate(TAF)and tenofovir disoproxil fumarate(TDF)in the treatment of chronic hepatitis B.Methods:A total of 84 patients with chronic hepatitis B treated in our hospital from May 2018 to May 2020 were selected and divided into two groups according to the random number table method,each with 42 cases.The control group was treated with oral TDF,and the observation group was treated with oral TAF.They were treated for 6 months.The clinical efficacy,liver function and adverse reactions of the two groups were compared.Results:The total effective rate and the levels of alanine aminotransferase(ALT)and aspartate aminotransferase(AST)before and after treatment were not statistically different between the two groups(P>0.05).The levels of ALT and AST in the two groups after treatment were all lower than those before treatment(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion:TAF or TDF treatment in patients with chronic hepatitis B can achieve the purpose of treatment,promote patient recovery and improve liver function,but TAF treatment is safer in clinical application.